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Abstract 
Review on t(11;19)(q23;p13), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Acute myeloid leukemia 
Phenotype/cell stem origin 
Seven cases are available, six of them were infant 
patients. Two were diagnosed with acute monocytic 
leukemia (AMoL) (Taki et al., 2005; Duhoux et al., 
2011). There were also 4 other cases of infant AML, 
not otherwise specified (NOS) (Lo Nigro et al., 
2002; Meyer et al. 2013) and 1 pediatric AML-NOS 
(Meyer et al. 2013). 
Epidemiology 
In the large study by Meyer et al., 2013, the four 
cases (3 infant AML, 1 pediatric AML) were part of 
a series of 692 infant ALL, 160 infant AMLs, 339 
pediatric AMLs, 313 pediatric ALLs, 415 adult 
ALLs and 373 adult AMLs. This chromosome 
abnormality seems so far restricted to a subset of 
patients: extremely young patients with a diagnosis 
of AML. 
Clinics 
One patient was diagnosed at birth (Duhoux et al., 
2011), and another one at 2 months of age (Taki et 
al., 2005). 
Prognosis 
Scarce data: one patient died 5 days after admission 
(Taki et al., 2005). 
Cytogenetics 
Cytogenetics morphological 
The t(11;19)(q23;p13.3) was the sole abnormality in 
the case described by Duhoux et al., 2011, while the 
cases of Lo Nigro et al., 2002 and Taki et al., 2005 
were complex translocations. 
Genes involved and 
proteins 
KMT2A (myeloid/lymphoid or mixed 
lineage leukemia) 
Location 
11q23.3 
DNA/RNA 
37 exons, spanning about 120 kb; 13-15 mRNA 
Protein 
3969 amino acids, 431 kDa; Transcriptional 
regulatory factor. MLL is known to be associated 
with more than 30 proteins, including the core 
components of the SWI/SNF chromatin remodeling 
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complex and the transcription complex TFIID. MLL 
binds promotors of HOX genes through acetylation 
and methylation of histones. MLL is a major 
regulator of hematopoesis and embryonic 
development, through regulation of HOX genes 
expression regulation ( HOXA9 in particular). 
MYO1F 
Location 
19p13.2 
DNA/RNA 
28 exons, 3297 nucleotides 
Protein 
1,098 amino acids; 124 KDa; Myosins are a large 
family of ATP-driven mechanoenzymes. MYO1F 
belong to myosin class I, which includes myosins 
that are able to interact with actin filaments and lipid 
membranes. Presence of three tail homology regions 
(TH1, TH2 and a SH3 domain named TH3). These 
"long-tailed" myosins (i.e. with additional TH2 and 
TH3) are able to crosslink actin filaments via the 
TH2 domain and generate mechanical activities 
using the actin cytoskeleton as a tract. MYO1F 
contains a myosin motor domain (amino acids 17 - 
690); this motor domain contains an actin binding 
site. It has an ATPase activity/cycle with 
association/dissociation of myosin with actin. The 
motor domain is followed by an IQ domain 
(isoleucine/glutamine motifs, aa 693 - 722), and a 
TH1 domain (Tail Homology domain, aa 728 - 917). 
TheTH1 domain is responsible for membrane 
interaction and, within TH1, a pleckstrin homology 
PH domain which is a negatively charged 
phospholipids -binding motif. There are several 
phosphosites located in the TH2 domain, required 
for binding to microtubules and microfilaments. 
TH2 is alanine and proline-rich (aa 941 - 1000). The 
C-terminus is a SH3 domain (SRC Homology 3 
domain, aa 1041 - 1098); it should mediate assembly 
of specific protein complexes via binding to proline-
rich peptides. TLR4 activation induces 
phosphorylation of MYO1F. MYO1F is a cytosolic 
protein predominantly expressed in the immune 
system (Wenzel et al., 2015; Walklate et al., 2016). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
KMT2A exon 9 was fused to MYO1F exon 2; the 
breakpoint was thus located within MLL intron 9 in 
the cases reported by Taki et al., 2005 and Duhoux 
et al., 2011. The breakpoint in KMT2A was in intron 
10 in cases studied by Meyer et al. 2013. 
Fusion protein 
 
KMT2A_MYO1F fusion protein, with AT hooks, zinc fingers CXXC type from KMT2A in N-terminus, fused to 
the entire MYO1F protein in C-terminus.
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